M. Alexander Otto
Medical Journalist at Medscape
Physician assistant, journalist. Over 20 years covering medicine. MIT journalism fellow, WebMD reporter. McClatchy, Bloomberg BNA, Washington Post background.
Articles
-
3 weeks ago |
medscape.com | M. Alexander Otto
The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without inhibitors. Fitusiran is a first-in-class small interfering RNA therapeutic that reduces antithrombin production in the liver by downgrading antithrombin gene expression. Antithrombin is a protein that inhibits clot formation.
-
1 month ago |
medscape.com | M. Alexander Otto
Cancer guidelines have long recommended that women with suspected ovarian cancer be seen by a gynecologic oncologist, but a third of women with ovarian cancer in the United States never see one. “They never make it to one of the doctors in this room,” said gynecologic oncologist Anna Jo Smith, MD, while speaking at a session of the Society of Gynecologic Oncology Annual Meeting on Women’s Cancers (SGO) 2025 in Seattle.
-
1 month ago |
medscape.com | M. Alexander Otto
The Mayo Clinic and Xact Sciences are developing an easy, noninvasive test to detect endometrial cancer in women with abnormal vaginal bleeding. It analyzes vaginal fluid collected on tampons for methylated DNA biomarkers of endometrial cancer. An earlier version of the test required 33 biomarkers, but investigators have since whittled it down to just six. The latest study results were announced at the Society of Gynecologic Oncology Annual Meeting in Seattle.
-
1 month ago |
medscape.com | M. Alexander Otto
Cryotherapy is emerging as a promising, low-risk approach to combat chemotherapy-induced peripheral neuropathy, a common and potentially devastating toxicity of chemotherapy. A growing body of research suggests that cryotherapy, or cold therapy, significantly reduces the incidence of this chemotherapy-induced nerve damage, especially among patients receiving taxane-based chemotherapy.
-
1 month ago |
medscape.com | M. Alexander Otto
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express programmed death ligand-1 (PD-L1; ≥ 1). The new approval is the Chinese immune checkpoint inhibitor’s third within a year.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 161
- Tweets
- 271
- DMs Open
- Yes
important study for oncologists https://t.co/PdlN59TZlo
[tweet to keep acct active]
Fresh of the press. Indeed, it is a nasty little bug, but things are looking up on Long Island, anyways. Can you imagine 70 people all intubated at once? Like a sci-fi nightmare... @MDEdgeTweets @AmerMedicalAssn @Medscape @ivanoransky @hmkyale https://t.co/qKf5eZAwa8